Your browser doesn't support javascript.
loading
Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement.
Yu, Ling; Lin, Jietao; Li, Hanhan; Sun, Lingling; Wang, Shubo; Chen, Yaoxu; Chen, Hanrui; Lin, Lizhu.
Afiliação
  • Yu L; Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Lin J; Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Li H; Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Sun L; Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Wang S; The Medical Department, 3D Medicines Inc., Shanghai, China.
  • Chen Y; The Medical Department, 3D Medicines Inc., Shanghai, China.
  • Chen H; Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Lin L; Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Front Pharmacol ; 14: 997760, 2023.
Article em En | MEDLINE | ID: mdl-36755949
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article